Valuation: Alvotech

Market Cap 1.71B 1.53B 1.41B 1.28B 2.4B 162B 2.44B 16.96B 6.68B 84.84B 6.42B 6.28B 269B P/E 2026 *
115x
P/E 2027 * 16x
Enterprise Value 2.79B 2.49B 2.29B 2.08B 3.91B 264B 3.97B 27.63B 10.88B 138B 10.45B 10.23B 438B EV / Sales 2026 *
4.27x
EV / Sales 2027 * 3.52x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day+0.20%
1 week-3.39%
Current month-11.55%
1 month-12.16%
3 months+60.82%
6 months+46.57%
1 week 4.79
Extreme 4.79
5.45
1 month 4.79
Extreme 4.79
6.53
Current year 2.94
Extreme 2.94
6.53
1 year 2.94
Extreme 2.94
8.5
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 2026-02-28
Director of Finance/CFO 48 2025-07-09
Chief Tech/Sci/R&D Officer - 2022-12-31
Director TitleAgeSince
Chairman 57 2018-12-31
Director/Board Member 64 2018-12-31
Director/Board Member 58 2018-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
4/1/26 Free

Chief Executive Officer

117,271 0.0355%
4/1/26 Sell

Founder

318,000 0.0963%
4/1/26 Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%-3.39%-37.67%-40.90% 1.71B
-4.10%-8.54%+40.05%+66.99% 63.29B
-1.00%+6.60%+10.08%+72.01% 54.89B
-0.19%+3.84%+9.27%+91.45% 53.28B
+0.61%+2.69%+27.75%+50.97% 45.81B
-1.08%+2.19%+21.92%+131.38% 43.46B
-3.39%-0.83%+254.27%+571.04% 40.23B
-1.67%+6.70%+14.42%+56.67% 33.45B
+1.19%-4.98%+29.01%-0.76% 23.7B
-0.96%+5.16%+35.76%+26.92% 23.76B
Average -1.03%+0.08%+40.49%+102.58% 38.36B
Weighted average by Cap. -1.38%+0.58%+46.90%+121.30%

Financials

2026 *2027 *
Net sales 653M 583M 537M 488M 916M 61.82B 930M 6.47B 2.55B 32.39B 2.45B 2.4B 103B 786M 702M 647M 588M 1.1B 74.44B 1.12B 7.8B 3.07B 39B 2.95B 2.89B 124B
Net income 2.25M 2M 1.85M 1.68M 3.15M 213M 3.2M 22.28M 8.78M 111M 8.43M 8.25M 353M 80.1M 71.5M 65.96M 59.93M 112M 7.59B 114M 795M 313M 3.98B 301M 294M 12.59B
Net Debt 1.08B 960M 886M 805M 1.51B 102B 1.53B 10.67B 4.2B 53.38B 4.04B 3.95B 169B 1.06B 943M 870M 790M 1.48B 100B 1.5B 10.48B 4.13B 52.4B 3.96B 3.88B 166B
Projected Income Statement - Annual - Alvotech
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
26-10-22 $4.790 -6.63% 926,997
26-10-21 $5.130 +0.20% 480,527
26-10-20 $5.120 +1.79% 1,302,515
26-10-19 $5.030 +0.60% 907,729
26-10-16 $5.000 -5.84% 1,059,087
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Alvotech
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.790USD
Average target price
7.200USD
Spread / Average Target
+50.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alvotech
  1. Stock Market
  2. Stocks
  3. ALVO Stock